Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.
Opthea Limited (ASX: OPT) generates frequent news as a clinical-stage biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Company announcements describe the progress of its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor studied in combination with standard-of-care anti-VEGF-A therapies.
News items for OPT commonly cover clinical milestones, including Phase 2b and Phase 3 trial updates in wet AMD, early-stage data in DME, and presentations of trial results and subgroup analyses at scientific meetings and in peer-reviewed journals. Opthea also releases updates on manufacturing activities, such as completion of drug substance and drug product Process Performance Qualification campaigns to support potential regulatory filings.
Investors following OPT news will also see corporate and capital markets developments. These include half-year financial reports, cash runway commentary, capital raising outcomes, and details of a Development Funding Agreement and its subsequent settlement. The company has reported that primary endpoints were not met in its COAST and ShORe Phase 3 wet AMD trials and has described the decision, together with its DFA investors, to discontinue development of sozinibercept in wet AMD, along with workforce reductions, management changes, and a planned strategic review.
Regulatory and listing updates also appear in Opthea’s news flow, such as announcements related to its intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. For readers interested in the intersection of ophthalmology, clinical trial data, and biotech corporate strategy, the OPT news feed provides ongoing context on Opthea’s programs and corporate actions.
Summary not available.
Summary not available.
Summary not available.
Opthea Limited (ASX:OPT; Nasdaq:OPT) has announced the receipt of an A$8.7 million (US$6.3 million) R&D tax credit from the Australian Taxation Office for the financial year 2021/2022. This incentive relates to costs incurred for developing its lead candidate OPT-302, which is in Phase 3 trials for wet age-related macular degeneration (wet AMD). The R&D Tax Incentive allows companies to claim 43.5% of eligible R&D expenditures. CEO Dr. Megan Baldwin stated that this funding strengthens Opthea's cash position as the company advances its clinical trials addressing unmet medical needs in retinal diseases.
Opthea Limited (NASDAQ:OPT; ASX:OPT), a biopharmaceutical company focused on innovative therapies for retinal diseases, announced that CEO Dr. Megan Baldwin will engage in a fireside chat at Oppenheimer's 33rd Annual Healthcare Conference on March 13, 2023, at 2:40 pm ET. This event can be accessed live through registration. Opthea’s lead candidate, OPT-302, is currently undergoing pivotal Phase 3 trials aimed at treating conditions like wet AMD and diabetic macular edema. The company emphasizes the risks associated with biotechnology investments, urging potential investors to seek professional advice.
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced the publication of Phase 2b study results for its anti-VEGF-C/-D agent, OPT-302, in Ophthalmology. The trial, involving 366 patients with wet age-related macular degeneration (AMD), showed that OPT-302 combined with ranibizumab significantly improved visual acuity compared to ranibizumab alone. Secondary outcomes also indicated better vision gains and reduced swelling. The FDA has granted OPT-302 Fast Track Designation, facilitating its ongoing Phase 3 trials aimed at further assessment of this combination therapy.
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced that Dr. Megan Baldwin, CEO, will present at the SVB Leerink Global Biopharma Conference from February 14-16, 2023. Her presentation is scheduled for February 15 at 5:00 PM ET (9:00 AM AEDT). The presentation will be archived and available for viewing at Opthea's website.
Opthea is focused on developing treatments for retinal diseases like wET AMD and DME, with its lead candidate OPT-302 in pivotal Phase 3 trials. Investors should note the inherent risks in biotechnology investing.
Opthea Limited announced that Dr. Megan Baldwin, CEO, will present at the Sequire Biotechnology Conference on February 2, 2023, at 10:00 am ET (2:00 am AEDT). Interested participants can register at Sequire's website.
Opthea is focused on developing therapies for retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema. Their lead product, OPT-302, is in pivotal Phase 3 trials aimed at enhancing efficacy when combined with existing treatments.
Investors are cautioned about the inherent risks in biotechnology investments, emphasizing the speculative nature of such opportunities.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced an 'Ask the Expert' conference call with Professor Jason S. Slakter on December 13, 2022. The session will cover Opthea's clinical trial programs for treating retinal diseases, specifically focusing on the management of wet AMD and the role of OPT-302. Participants can submit questions in advance. The company is developing therapies addressing unmet needs in wet age-related macular degeneration and diabetic macular edema, with OPT-302 undergoing pivotal Phase 3 trials.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced a podium presentation at the FLORetina congress in Rome from December 8-11, 2022. Dr. Caroline Baumal from Tufts University will discuss OPT-302 combination therapy in wet AMD. The presentation, titled New approach in wet-AMD treatment: Efficacy and safety of dual inhibition of VEGF-C/-D and VEGF-A with OPT-302 combination therapy, is scheduled for December 10, 2022, from 1:09 PM to 1:30 PM. Opthea is advancing its lead product, OPT-302, through Phase 3 trials targeting improved treatment outcomes for retinal diseases.
FAQ
What is the current stock price of Opthea (OPT)?
What is the market cap of Opthea (OPT)?
